Cyld-mediated signaling and diseases

Current Drug Targets

Volumn 16, Issue 4, 2015, Pages 284-294

  Mathis, Bryan J ^a   Lai, Yimu ^a   Qu, Chen ^a   Janicki, Joseph S ^a   Cui, Taixing ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular; CYLD; Cylindromatosis; Deubiquitination; K63; MAPK; NF kB

Indexed keywords

CYCLINE; DEUBIQUITINASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE DEACETYLASE 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PROTEIN P62; RANTES; REACTIVE OXYGEN METABOLITE; RETINOIC ACID INDUCIBLE PROTEIN I; TAX PROTEIN; TRANSCRIPTION FACTOR SNAIL; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; AUTACOID; CYLD PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; AUTOPHAGY; CARDIOVASCULAR DISEASE; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CYLINDROMATOSIS GENE; ENZYME ACTIVITY; ENZYME REGULATION; GENE; GENE EXPRESSION; GENE MUTATION; HOMEOSTASIS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION; INFLAMMATION; INTRACELLULAR SIGNALING; MITOSIS SPINDLE; MONOCYTE; NECROSIS; NONHUMAN; PHOSPHORYLATION; REGULATOR GENE; SMOOTH MUSCLE FIBER; UBIQUITINATION; VASCULAR LESION; WNT SIGNALING PATHWAY; ANIMAL; CARDIOVASCULAR SYSTEM; CELL CYCLE; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL CYCLE; HUMANS; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84928891186     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141024152421     Document Type: Article

References (139)

1. [I] Biggs PJ, Wooster R, Ford D, et al. Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12- q13: evidence for its role as a tumour suppressor gene. Nat Genet 1995; 11(4): 441-3.
2. [2] Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000; 25(2): 160-5.
3. [3] Poblete Gutiérrez P, Eggermann T, Höller D, et al. Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages. J Invest Dermatol 2002; 119(2):527-31.
4. [4] Brummelkamp TR, Nijman SMB, Dirac AMG, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424(6950): 797-801.
5. 5[] Regamey A, Hohl D, Liu JW, et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med 2003 15; 198(12): 1959-64.
6. [6] Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424(6950): 793-6.
7. [7] Kovalenko A, Chable-bessia C, The tumour suppressor CYLD negatively regulates NF- k B signalling by deubiquitination. Nature 2003; 801-5.
8. [8] Saito K, Kigawa T, Koshiba S, et al. The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma. Structure 2004; 12(9): 1719-28.
9. [9] Lian F, Cockerell CJ. Cutaneous appendage tumors: familialcylindromatosis and associated tumors update. Adv Dermatol 2005; 21: 217-34.
10. [10] Massoumi R, Paus R. Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. Bioessays 2007; 29(12): 1203-14.
11. [11] Yoshida H, Jono H, Kai H, Li J-D. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 2005; 280(49): 41111-21.
12. [12] Besse A, Campos AD, Webster WK, Darnay BG. TRAF-interacting protein (TRIP) is a RING-dependent ubiquitin ligase. Biochem Biophys Res Commun 2007; 359(3): 660-4.
13. [13] Liu S, Lv J, Han L, et al. A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells. Biochem Biophys Res Commun 2012; 420(1): 78-83.
14. [14] Trompouki E, Tsagaratou A, Kosmidis SK, et al. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 2009; 11(5): 469-76.
15. [15] Blake PW, Toro JR. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat 2009; 30(7): 1025-36.
16. [16] Sundaram K, Shanmugarajan S, Rao DS, Reddy SV. Mutant p62P392L stimulation of osteoclast differentiation in Paget’s disease of bone. Endocrinology 2011; 152(11): 4180-9.
17. [17] Hayashi M, Jono H, Shinriki S, et al. Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat 2014; 143(3): 447-57.
18. [18] Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fässler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125(4): 665-77.
19. [19] Lim JH, Jono H, Komatsu K, et al. CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat Commun 2012; 3: 771.
20. [20] Lim JH, Stirling B, Derry J, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007; 27(2): 349-60.
21. [21] Lim JH, Ha U-H, Woo C-H, Xu H, Li J-D. CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia. Cell Microbiol 2008; 10(11): 2247-56.
22. [22] Lim JH, Jono H, Koga T, et al. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One 2007; 2(10): e1032.
23. [23] Komander D, Lord CJ, Scheel H, et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 2008; 29(4): 451-64.
24. [24] Weissman Institute. Cited 2014 May 5. Available from: www.genecards.org
25. [25] Komander D. CYLD tidies up dishevelled signaling. Mol Cell 2010; 37(5): 589-90.
26. [26] Chu Y, Soberon V, Glockner L, et al. A20 and CYLD do not share significant overlapping functions during B cell development and activation. J Immunol 2012; 189(9): 4437-43.
27. [27] Reiley W, Zhang M, Wu X, Granger E, Sun S. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol 2005; 25(10): 3886-95.
28. [28] Wu P, Shi KJ, An JJ, et al. The LEF1/CYLD axis and cIAPs regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis 2014; 5: e1085.
29. [29] Kirchhofer D, Vucic D. Protease activity of MALT1: a mystery unravelled. Biochem J 2012; 444(2): e3-5.
30. [30] Liang G, Ahlqvist K, Pannem R, Posern G, Massoumi R. Serum response factor controls CYLD expression via MAPK signaling pathway. PLoS One 2011; 6(5): e19613.
31. [31] Thein S, Tao-Cheng J-H, Li Y, Bayer KU, Reese TS, Dosemeci A. CaMKII mediates recruitment and activation of the deubiquitinase CYLD at the postsynaptic density. PLoS One 2014; 9(3):e91312.
32. [32] Massoumi R, Kuphal S, Hellerbrand C, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009; 206(1): 221-32.
33. [33] Takiuchi T, Nakagawa T, Tamiya H, et al. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. Genes Cells 2014; 19(3): 254-72.
34. [34] Liu P, Xu B, Shen W, et al. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia 2012; 26(6): 1293-300.
35. [35] Kuphal S, Shaw-Hallgren G, Eberl M, et al. GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma. Oncogene 2011; 30(44): 4523-30.
36. [36] D’Altri T, Gonzalez J, Aifantis I, Espinosa L, Bigas A. Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia. Cell Cycle 2011; 10(7): 1031-6.
37. [37] Xia J, Chen L, Jian W, et al. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med 2014; 12: 33.
38. [38] Kim S-J, Jung H-J, Lim C-J. Reactive Oxygen Species-Dependent Down-Regulation of Tumor Suppressor Genes PTEN, USP28, DRAM, TIGAR, and CYLD Under Oxidative Stress. Biochem Genet 2013; 51(11-12): 901-15
39. [39] Sun S-C. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010; 17(1): 25-34.
40. [40] O’Donnell MA, Perez-Jimenez E, Oberst A, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol 2011; 13(12): 1437-42.
41. [41] Goncharov T, Niessen K, de Almagro MC, et al. OTUB1 modulates c-IAP1 stability to regulate signalling pathways. EMBO J 2013; 32(8): 1103-14.
42. [42] Dimitrov S, Sabherwal Y, Raymond DD, L’Heureux DZ, Lu Q, Tuszynski GP. Endothelial apoptotic activity of angiocidin is dependent on its polyubiquitin binding activity. Br J Cancer 2005; 93(6): 662-9.
43. [43] Ciehanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 1978; 81(4): 1100-5.
44. [44] Driscoll J, Goldberg AL. The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins. J Biol Chem 1990; 265(9): 4789-92.
45. [45] Willis MS, Townley-tilson WHD, Kang EY, Jonathon W, Patterson C. Sent to Destroy: The Ubiquitin Proteasome System Regulates Cell Signaling and Protein Quality Control in Cardiovascular Disease. Circ Res 2011; 106(3): 463-78.
46. [46] Harhaj EW, Dixit VM. Regulation of NF-κB by deubiquitinases.Immunol Rev 2012; 246(1): 107-24.
47. [47] Komander D. The emerging complexity of protein ubiquitination.Biochem Soc Tran 2009; 37(Pt 5): 937-53
48. [48] Varadan R, Assfalg M, Haririnia A, Raasi S, Pickart C, Fushman D. Solution conformation of Lys63-linked di-ubiquitin chain provides clues to functional diversity of polyubiquitin signaling. J Biol Chem 2004; 279(8): 7055-63.
49. [49] Zhao S, Ulrich HD. Distinct consequences of posttranslational modification by linear versus K63-linked polyubiquitin chains. Proc Natl Acad Sci USA 2010; 107(17): 7704-9.
50. [50] Bremm A, Freund SM V, Komander D. Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne. Nat Struct Mol Biol 2010; 17(8): 939-47.
51. [51] Medina R, Wing SS, Goldberg a L. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 1995; 307 (Pt 3): 631-7.
52. [52] Adam PJ, Weissberg PL, Cary NR, Shanahan CM. Polyubiquitin is a new phenotypic marker of contractile vascular smooth muscle cells. Cardiovasc Res 1997; 33(2): 416-21.
53. [53] Zhao Y, Zhu H, Zou M-H. Non-covalent interaction between polyubiquitin and GTP cyclohydrolase 1 dictates its degradation. PLoS One 2012; 7(9): e43306.
54. [54] Delfino M, D’Anna F, Ianniello S, Donofrio V. Multiple hereditary trichoepithelioma and cylindroma (Brooke-Spiegler syndrome). Dermatologica 1991; 183(2): 150-3.
55. [55] Korting HC, Konz B. [Coincidence of multiple cylindroma and trichoepitheliomas (Brooke-Spiegler-Syndrome)]. Hautarzt 1982; 33(1): 34-46.
56. [56] Dosemeci A, Thein S, Yang Y, Reese TS, Tao-Cheng J-H. CYLD, a deubiquitinase specific for lysine63-linked polyubiquitins, accumulates at the postsynaptic density in an activity-dependent manner. Biochem Biophys Res Commun 2013; 430(1): 245-9.
57. [57] Alameda JP, Fernández-Aceñero MJ, Moreno-Maldonado R, et al. CYLD regulates keratinocyte differentiation and skin cancer progression in humans. Cell Death Dis 2011; 2: e208.
58. [58] Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012; 21(6): 738-50.
59. [59] Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, Massoumi R. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis 2014; 35(2): 461-8.
60. [60] Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K, STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39(4): 493-506.
61. [61] Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26(3): 203-34.
62. [62] Laplantine E, Fontan E, Chiaravalli J, et al. NEMO specifically recognizes K63-linked poly-ubiquitin chains through a new bipartite ubiquitin-binding domain. EMBO J 2009; 28(19): 2885-95.
63. [63] Hadian K, Griesbach RA, Dornauer S, et al. NF-κB essential modulator (NEMO) interaction with linear and lys-63 ubiquitin chains contributes to NF-κB activation. J Biol Chem 2011; 286(29): 26107-17.
64. [64] Reiley WW, Zhang M, Jin W, et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006; 7(4): 411-7.
65. [65] Jin W, Reiley WR, Lee AJ, et al. Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J Biol Chem. 2007; 282(21): 15884-93.
66. [66] Thuille N, Wachowicz K, Hermann-Kleiter N, et al. PKCθ/β and CYLD are antagonistic partners in the NFκB and NFAT transactivation pathways in primary mouse CD3+ T lymphocytes. PLoS One 2013; 8(1): e53709.
67. [67] Reissig S, Hövelmeyer N, Weigmann B, et al. The tumor suppressor CYLD controls the function of murine regulatory T cells. J Immunol 2012; 189(10): 4770-6.
68. [68] Hövelmeyer N, Wunderlich FT, Massoumi R, et al. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J Exp Med 2007; 204(11): 2615-27.
69. 69[] Liu X, Chen W, Wang Q, Li L, Wang C, Negative regulation of TLR inflammatory signaling by the SUMO-deconjugating enzyme SENP6. PLoS Pathog 2013; 9(6): e1003480.
70. [70] Bros M, Dexheimer N, Besche V, et al. Mutated cylindromatosis gene affects the functional state of dendritic cells. Eur J Immuno 2010; 40(10): 2848-57.
71. [71] Zhang M, Wu X, Lee AJ, et al. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J Biol Chem 2008; 283(27): 18621-6.
72. [72] Manganaro L, Pache L, Herrmann T, et al. Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in a NF-κB dependent manner. J Virol 2014; 88(13): 7528-40
73. 73[] Nishanth G, Deckert M, Wex K, Massoumi R, Schweitzer K, Naumann M, et al. CYLD enhances severe listeriosis by impairing IL-6/STAT3-dependent fibrin production. PLoS Pathog 2013; 9(6): e1003455.
74. [74] Harhaj EW, Dixit VM. Deubiquitinases in the regulation of NF-κB signaling. Cell Res 2011; 21(1): 22-39.
75. [75] Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012; 246(1): 95-106.
76. [76] Ang E, Pavlos NJ, Rea SL, et al. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J Cell Physiol 2009; 220(2): 450-9.
77. [77] Cui T-G, Ichikawa T, Yang M, Dong X, Li J, Cui T. An emerging role of deubiquitinating enzyme cylindromatosis (CYLD) in the tubulointerstitial inflammation of IgA nephropathy. Biochem Biophys Res Commun 2009; 390(2): 307-12.
78. [78] Urbanik T, Köhler BC, Boger RJ, et al. Down-regulation of CYLD as a trigger for NF- κ B activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol 2011; 121-31.
79. [79] Hornbeck P V, Kornhauser JM, Tkachev S, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 2012; 40(Database issue): D261-70.
80. [80] Ahmed N, Zeng M, Sinha I, et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol 2011; 12(12): 1176-83.
81. [81] Deng LL, Shao YX, Lv HF, Deng HB, Lv FZ, Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells. Neoplasma 2012; 18-29.
82. [82] Komatsu K, Lee J-Y, Miyata M, et al. Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. Nat Commun 2013; 4: 1684.
83. [83] Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 2007; 104(21): 8869-74.
84. [84] Liu D, Davydenko O, Lampson MA. Polo-like kinase-1 regulates kinetochore-microtubule dynamics and spindle checkpoint silencing. J Cell Biol 2012; 198(4): 491-9.
85. [85] Gao J, Huo L, Sun X, et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 2008; 283(14): 8802-9.
86. [86] Gao J, Sun L, Huo L, Liu M, Li D, Zhou J. CYLD regulates angiogenesis by mediating vascular endothelial cell migration. Blood 2010; 115(20): 4130-7.
87. [87] Gomez-Ferreria MA, Bashkurov M, Mullin M, Gingras A-C, Pelletier L. CEP192 interacts physically and functionally with the K63-deubiquitinase CYLD to promote mitotic spindle assembly. Cell Cycle 2012; 11(19): 3555-8.
88. [88] Yang Y, Sun L, Tala, et al. CYLD regulates RhoA activity by modulating LARG ubiquitination. PLoS One 2013; 8(2): e55833.
89. [89] Reiley W, Zhang M, Sun S-C. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 2004; 279(53): 55161-7.
90. [90] Yang Y, Liu M, Li D, et al. CYLD regulates spindle orientation by stabilizing astral microtubules and promoting dishevelled-NuMA-dynein/dynactin complex formation. Proc Natl Acad Sci USA 2014; 111(6): 2158-63.
91. [91] Espinosa L, Cathelin S, D’Altri T, et al. The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18(3): 268-81.
92. [92] Tauriello DVF, Haegebarth A, Kuper I, et al. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 2010; 37(5): 607-19.
93. [93] Masckauchán TNH, Shawber CJ, Funahashi Y, Li C-M, Kitajewski J. Wnt/beta-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 2005; 8(1): 43-51.
94. [94] Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012; 81: 203-29.
95. 95[] Yang W-L, Jin G, Li C-F, et al. Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal 2013; 6(257): ra3.
96. [96] Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26(4): 239-57.
97. [97] Sheridan JW, Bishop CJ, Simmons RJ. Biophysical and morphological correlates of kinetic change and death in a starved human melanoma cell line. J Cell Sci 1981; 49: 119-37.
98. [98] Neal J V, Potten CS. Effect of low dose ionizing radiation on the murine pericryptal fibroblast sheath: radiation damage in a mesenchymal system in vivo. Int J Radiat Biol Relat Stud Phys Chem Med 1981; 39(2): 175-83.
99. 99[] Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson’s disease: signals for neuronal degradation. Ann Neurol 2003; 53 Suppl 3: S61-70; discussion S70-2.
100. [100] Ferrer I, Planas AM. Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J Neuropathol Exp Neurol 2003; 62(4): 329-39.
101. [101] Gao Y, Signore AP, Yin W, et al. Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway. J Cereb Blood Flow Metab 2005; 25(6): 694-712.
102. [102] Sawai H, Domae N. Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells. Biochem Biophys Res Commun 2011; 411(3): 569-73.
103. [103] Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011; 108(8): 1017-36.
104. [104] Li J, McQuade T, Siemer AB, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 2012; 150(2): 339-50.
105. [105] Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137(6): 1112-23.
106. 106[] Vandenabeele P, Declercq W, Van Herreweghe F, Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 2010; 3(115): re4.
107. [107] Sosna J, Voigt S, Mathieu S, et al. TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death. Cell Mol Life Sci 2014; 71(2): 331-48.
108. [108] Linkermann A, Bräsen JH, De Zen F, et al. Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor-α-induced shock. Mol Med 2012; 18: 577-86.
109. [109] Moquin DM, McQuade T, Chan FK-M. CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS One 2013; 8(10): e76841.
110. [110] Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12(11): 1539-46.
111. [111] Vandenabeele P, Grootjans S, Callewaert N, Takahashi N. Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models. Cell Death Differ 2013; 20(2): 185-7.
112. [112] Kim SJ, Li J. Caspase blockade induces RIP3-mediated programmed necrosis in Toll-like receptor-activated microglia. Cell Death Di. 2013; 4: e716.
113. [113] Schworer SA, Smirnova II, Kurbatova I, et al. Toll-like Receptor-Mediated Downregulation of the Deubiquitinase CYLD Protects Macrophages from Necroptosis in Wild-Derived Mice. J Biol Chem 2014; 289(20): 14422-33
114. [114] Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012; 298: 229-317.
115. [115] Duval CW. The experimental vascular lesions produced by Bacillus mallei. J Exp Med 1907; 9(3): 241-53.
116. [116] Doornekamp FN, Borst C, Post MJ. Endothelial cell recoverage and intimal hyperplasia after endothelium removal with or without smooth muscle cell necrosis in the rabbit carotid artery. J Vasc Res 1996; 33(2): 146-55.
117. [117] Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92(5): 1355-74.
118. [118] Schwenke DC, Carew TE,Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arterioscler Thromb Vasc Biol 1989; 9(6): 908-18.
119. [119] Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997; 96(11): 4095-103.
120. [120] Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473(7347): 317-25.
121. [121] Park HS, Hahn S, Choi GH, Yoo YS, Lee JY, Lee T. Muscle-derived stem cells promote angiogenesis and attenuate intimal hyperplasia in different murine vascular disease models. Stem Cells Dev 2013; 22(6): 866-77.
122. [122] Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5’ enhancer. Circ Res 1995; 77(3): 638-43.
123. [123] Shi N, Xie W, Chen S-Y. Cell division cycle 7 is a novel regulator of transforming growth factor-β-induced smooth muscle cell differentiation. J Biol Chem 2012; 287(9): 6860-7.
124. [124] Witmer LM. Clinical Anatomy of the Aorta. Athens, OH: The Ohio State University; 2014. p. 1-15.
125. [125] Banerjee I, Fuseler JW, Price RL, Borg TK, Baudino TA. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 2007; 293(3): H1883-91.
126. [126] Takami Y, Nakagami H, Morishita R, K et al. Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells. Am J Pathol 2008; 172(3): 818-29.
127. 127[] Hotchkiss A, Robinson J, MacLean J, Feridooni T, Wafa K, Pasumarthi KBS. Role of D-type cyclins in heart development and disease. Can J Physiol Pharmacol 201; 90(9): 1197-207.
128. [128] Iha H, Peloponese J-M, Verstrepen L, et al. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-kappaB activation. EMBO J 2008; 27(4): 629-41.
129. [129] Wu X, Zhang M, Sun S-C. Mutual regulation between deubiquitinase CYLD and retroviral oncoprotein Tax. Cell Biosci 2011; 1(1): 27.
130. [130] Harikumar KB, Yester JW, Surace MJ, et al. K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat Immunol 2014; 15(3): 231-8.
131. [131] Mitra S, Sammani S, Wang T, et al. Role of growth arrest and DNA damage-inducible α in Akt phosphorylation and ubiquitination after mechanical stress-induced vascular injury. Am J Respir Crit Care Med 2011; 184(9): 1030-40.
132. 132[] Ichikawa T, Li J, Dong X, et al. Ubiquitin carboxyl terminal hydrolase L1 negatively regulates TNFalpha-mediated vascular smooth muscle cell proliferation via suppressing ERK activation. Biochem Biophys Res Commun 2010 1; 391(1): 852-6.
133. [133] Wickström SA, Masoumi KC, Khochbin S, Fässler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J 2010; 29(1): 131-44.
134. [134] Depre C, Wang Q, Yan L, et al., Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 2006; 114(17): 1821-8.
135. [135] Tannous P, Zhu H, Johnstone JL, et al. Autophagy is an adaptive response in desmin-related cardiomyopathy. Proc Natl Acad Sci USA 2008; 105(28): 9745-50.
136. [136] Banerjee P, Basu A, Wegiel B, et al. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J Biol Chem 2012; 287(38): 32113-23.
137. [137] Tang D, Kang R, Livesey KM, Cheh C-W, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190(5): 881-92.
138. [138] Wirawan E, Vande Walle L, Kersse K, et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010; 1(1): e18.
139. [139] Reggiori F, Komatsu M, Finley K, Simonsen A. Autophagy: more than a nonselective pathway. Int J Cell Biol 2012; 2012(Fig. 1): 219625.